AIMS: To evaluate the prognostic impact of tumour angiogenesis assessed by vascular endothelial growth factor (VEGF), microvessel density (MVD), and tumour vessel invasion in patients who had undergone radical resection for stage IB-IIA non-small cell lung cancer (NSCLC). METHODS: Fifty one patients (42 men, nine women; mean age, 62.3 years; SD, 6.9) undergoing complete surgical resection (35 lobectomy, 16 pneumonectomy) of pathological stage IB (n = 43) and IIA (n = 8) NSCLC were evaluated retrospectively. No patient underwent postoperative chemotherapy or neoadjuvant treatment. Tumour specimens were stained for VEGF and specific MVD markers: CD31, CD34, and CD105. RESULTS: VEGF expression significantly correlated with high CD105 expression (p < 0.0001) and tumour vessel invasion (p = 0.04). Univariate analysis showed that those patients with VEGF overexpression (p = 0.0029), high MVD by CD34 (p = 0.0081), high MVD by CD105 (p = 0.0261), and tumour vessel invasion (p = 0.0245) have a shorter overall survival. Furthermore, multivariate Cox regression analysis showed that MVD by CD34 (p = 0.007), tumour vessel invasion (p = 0.024), and VEGF expression (p = 0.042) were significant predictive factors for overall survival. Finally, the presence of both risk factors, tumour vessel invasion and MVD by CD34, was highly predictive of poor outcome (odds ratio, 3.4; 95% confidence interval, 1.7 to 6.5; p = 0.0002). CONCLUSIONS: High MVD by CD34 and tumour vessel invasion are more closely related to poor survival than the other neoangiogenetic factors in stage IB-IIA NSCLC. This may be because these factors are more closely related to the metastatic process.
AIMS: To evaluate the prognostic impact of tumour angiogenesis assessed by vascular endothelial growth factor (VEGF), microvessel density (MVD), and tumour vessel invasion in patients who had undergone radical resection for stage IB-IIA non-small cell lung cancer (NSCLC). METHODS: Fifty one patients (42 men, nine women; mean age, 62.3 years; SD, 6.9) undergoing complete surgical resection (35 lobectomy, 16 pneumonectomy) of pathological stage IB (n = 43) and IIA (n = 8) NSCLC were evaluated retrospectively. No patient underwent postoperative chemotherapy or neoadjuvant treatment. Tumour specimens were stained for VEGF and specific MVD markers: CD31, CD34, and CD105. RESULTS:VEGF expression significantly correlated with high CD105 expression (p < 0.0001) and tumour vessel invasion (p = 0.04). Univariate analysis showed that those patients with VEGF overexpression (p = 0.0029), high MVD by CD34 (p = 0.0081), high MVD by CD105 (p = 0.0261), and tumour vessel invasion (p = 0.0245) have a shorter overall survival. Furthermore, multivariate Cox regression analysis showed that MVD by CD34 (p = 0.007), tumour vessel invasion (p = 0.024), and VEGF expression (p = 0.042) were significant predictive factors for overall survival. Finally, the presence of both risk factors, tumour vessel invasion and MVD by CD34, was highly predictive of poor outcome (odds ratio, 3.4; 95% confidence interval, 1.7 to 6.5; p = 0.0002). CONCLUSIONS: High MVD by CD34 and tumour vessel invasion are more closely related to poor survival than the other neoangiogenetic factors in stage IB-IIA NSCLC. This may be because these factors are more closely related to the metastatic process.
Authors: J M Siegfried; L A Weissfeld; J D Luketich; R J Weyant; C T Gubish; R J Landreneau Journal: Ann Thorac Surg Date: 1998-12 Impact factor: 4.330
Authors: H Han; J F Silverman; T S Santucci; R S Macherey; T A d'Amato; M Y Tung; R J Weyant; R J Landreneau Journal: Ann Surg Oncol Date: 2001 Jan-Feb Impact factor: 5.344
Authors: S Kakolyris; A Giatromanolaki; M Koukourakis; I M Leigh; V Georgoulias; P Kanavaros; E Sivridis; K C Gatter; A L Harris Journal: Cancer Res Date: 1999-11-01 Impact factor: 12.701
Authors: I G Duarte; B L Bufkin; M F Pennington; A A Gal; C Cohen; A S Kosinski; K A Mansour; J I Miller Journal: J Thorac Cardiovasc Surg Date: 1998-03 Impact factor: 5.209
Authors: F Tanaka; Y Otake; K Yanagihara; Y Kawano; R Miyahara; M Li; T Yamada; N Hanaoka; K Inui; H Wada Journal: Clin Cancer Res Date: 2001-11 Impact factor: 12.531
Authors: A Giatromanolaki; M I Koukourakis; D Theodossiou; K Barbatis; K O'Byrne; A L Harris; K C Gatter Journal: Clin Cancer Res Date: 1997-12 Impact factor: 12.531
Authors: Hester van Cruijsen; Mariëlle Gallegos Ruiz; Paul van der Valk; Tanja D de Gruijl; Giuseppe Giaccone Journal: BMC Cancer Date: 2009-06-11 Impact factor: 4.430